Methods: Electronic databases were searched (MEDLINE, EMBASE, CINAHL, AMED) up to July 2015 to identify studies with objective or subjective measures of SB, sample size ≥ 50, mean age ≥ 60 years and accelerometer wear time ≥3 days. Methodological quality was appraised with the CASP tool. The protocol was pre-specified (PROSPERO CRD42015023731).
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. . Recently, there has been an interest in understanding the biomarkers underlying the response to PA. For example, in a cohort of community dwelling older adults, levels of N-terminal pro-brain natriuretic peptide (NTproBNP) and high-sensitive troponin T have been associated with objectively monitored PA and showed a more beneficial profile with increasing PA, suggesting a dose response relationship 7, 8 . To date, most of the PA biomarker research has focussed on cardiovascular risk factors 5, 6, 7 , but there are many other . Older people are seen as the age group engaging in the highest level of SB 13 and thus could benefit most from changing their daily habits.
The developing evidence on the harms associated with SB has illustrated that it is not only the absence of daily or weekly moderate-to-vigorous physical activity (MVPA), but rather, SB is a separate category of behaviour with unique determinants, consequences and sequences for possible intervention 16 .
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Considering the physiological changes occurring with age in several organ systems 17 , results from middle-aged adults can't be simply transferred to older adults. Therefor the EU study SITLESS investigates how SB can be reduced sustainably and how sedentariness effects biomarkers especially in older adults. In this framework the interest on outcomes of studies performed in elderly, assessing SB and its impact on biomarkers was the focus. In addition, biomarker studies are important to further understand the link between SB, PA and adverse health outcomes like total mortality and harmful phenotypes like Metabolic Syndrome (MES) 21 , frailty or sarcopenia. Perhaps it can help to understand the role of biomarkers as possible mediators of the association between SB and adverse phenotypes or aging-related diseases. Therefore, the aims of this systematic review were to provide a comprehensive overview of aging-related biomarkers associated with SB and report on the strength of the observed associations in community-dwelling older adults.
Methods

Study design
This systematic review adhered to the PRISMA guidelines 22 and followed a predetermined published protocol (PROSPERO No. CRD42015023731) 23 .
Condition or domain being studied
SB, as defined by the Sedentary Behaviour Research Network 10 (waking behaviour with an energy expenditure ≤ 1.5 METs whilst in a sitting or reclining posture), represented our exposure of interest.
We also considered studies which did not fully comply with this definition (e.g. television watching time, SB identified by other questionnaires or accelerometer data that do not allow for disentangling posture issues or clearly indicate METs) but are highly relevant to SB.
With respect to the biomarkers we were interested in any inflammatory, renal and cardiac biomarkers, lipids and metabolic markers, genetic and metabolomics markers, endocrine markers and markers of muscle strength, body composition, as well as of specific physical performance measures (e.g. gait speed and balance).
Information sources and searches
Two authors (KW, BS) searched the electronic databases: MEDLINE (PubMed), EMBASE, CINAHL (via EBSCO), AMED (via Ovid/EBSCO) from inception to 15 July 2015. We used search terms described in appendix 1. Appropriate search strategies and MESH-terms were selected (see appendix 1).
Study selection and eligibility criteria
Studies meeting the following criteria were included: 1) Explicitly measured SB using objective (accelerometer wear time ≥ 3 days (to follow the recommendations of good clinical practice 24 ) or self-report instruments. Studies defining SB purely as a lack of PA were excluded.
2) Including community dwelling, older adults (mean age of sample ≥ 60 years).
3) Sample size of n ≥ 50 participants, to ensure adequate power.
4) Quantitative study design including randomized controlled trials (RCTs), controlled clinical trials (CCTs), pre-and post-intervention measurement studies, prospective observational studies (POS), or studies (only prospective trials) that examined an association of any biomarker with SB. We also considered cross-sectional studies (CSS) but present them separately because of their descriptive nature due to the inability to clearly establish the temporal sequence between SB and biomarkers.
Participants and population
We selected studies, with the above mentioned characteristics that included older adults (mean age ≥ 60 years) conducted in the community.
When we encountered studies with a large age range and a mean age below 60 years, indicating the study included some older adults (> 60 years), we attempted to contact the authors to acquire the variables of interest for all participants with an age of 60 years and older. Populations with specific comorbidity (e.g. diabetes mellitus type 2 (DM-II), peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD) were included, but critically evaluated and highlighted as such.
Data extraction
All results of the searches were inserted in a bibliographic database. A data extraction form was created and amended to the requirements of the review. Two authors piloted (KW; SB) the data extraction form in a random sample of 3 studies that employ different study designs. This ensured that the relevant information was selected to assess the effectiveness and study quality.
All data were extracted by these two reviewers. Data extraction included: first author, country, setting, population, aims of the study, type of the study (RCT, POS or CSS), number of studies and participants included in the article, details of the intervention (including duration), inclusion criteria, type of recruitment, type and definition of SB or PA used, biomarkers analysed and results, details of control condition, overall study quality (internal risk of bias), association statistics, acknowledged limitations by authors, the authors' conclusions and other notes.
Any disagreements in data extraction were resolved through discussion between the reviewers.
Risk of bias and quality assessment
Assessment of studies followed the PRISMA 22 guidelines. Two authors conducted the methodological quality appraisal of all included studies using a modified Critical Appraisal Skills Programme (CASP) tool, adapted for each study design 25 :
 RCTs (max. CASP score = 6) were assessed for risk of bias in the following domains: clearly focused issue, randomization, performance (blinding, personnel), comparability (treatment, groups at baseline) and attrition (participants accounted for at its conclusion).
 POS (max. CASP score = 8) were assessed for risk of bias in the following domains: clearly focused issue, selection and recruitment (random approach or representative for a defined population, accuracy of measurement (exposure, outcome), identification of important confounding factors, adjustment for confounding factors and follow-up (period, completion).
 CCS (max. CASP score = 6) were assessed for risk of bias in: clearly focused issue, selection and recruitment (random approach or representative for defined population), accuracy of measurement (exposure, outcome), identification of important confounding factors and adjustment for confounding factors.
In an attempt to assess the potential effect and direction of the effect of SB on specific biomarkers, additional information related to statistical evidence of an association, as adapted from the Canadian Agency for Drugs and Technology in Health (CADTH)
26
, was included in Table 2 for the high quality studies. The following decision rules as suggested by CADTH
, were used for standardized statements about the statistical significance:
 0% of studies showed statistically significant results = no evidence for any association  1% to 33% of studies showed statistically significant results = generally no evidence for any association.
 34% to 66% of studies showed statistically significant results = mixed evidence for association  67% or more studies showed statistically significant results = generally evidence for association
Due to the few studies of high quality, we decided to apply this method of categorisation, although often less than 5 studies with statistically significant results were found. To ensure a minimum level of validity, we applied this tool in all biomarkers measured in ≥ 3 studies (RCT and/or POS).
Strategy for data synthesis and subgroup analysis
We tabulated the single study results and grouped them according to comparable biomarkers. All results were stratified with appropriate subgroup analyses, for instance according to exposure type (SB and PA separately), type of SB/PA assessment (questionnaire-versus sensor-based), biomarker type and study design (RCT and CCT separately). We anticipated conducting a meta-analysis if sufficient homogeneity was evident across the study types and outcomes of interest and enough studies could be identified in comparable areas.
Results
Results of the literature search
Our initial searches identified 12,701 hits. After the exclusion at title level, removing of duplicates and the matching of results from the two independent reviewers (including removing duplicates), a final list of 275 full-text articles was scrutinised. 235 articles were subsequently excluded according to our inand exclusion criteria (full details in figure 1 ). 3 studies included people with a large age range in their sample, yet a mean age below 60 years. Upon 3 attempts to contact the authors, 1 group (Aadahl and colleagues 27 ) provided additional data, whilst 2 authors did not respond and were subsequently excluded due to age < 60 years (Knight et al. 28 and Mohri et al.
29
).
After exclusions, 40 studies were considered eligible, however after further revision and evaluation, another 14 articles (1 POS, 13 CSS) were excluded (for more details see "risk of bias (quality) appraisal"), thus leading to a total of 26 articles (4 RCT, 2 POS and 21 CSS). The study from Cooper at al. 30 was included as a POS and CSS due to longitudinal and cross-sectional analysis of the data reported by the study authors.
Definition of Sedentary Behaviour
We found a highly heterogeneous definition of SB, which was often misclassified as simply the absence of PA and therefor 134 papers were excluded. The most frequent definition of SB was total time spent at less than 100 counts per minute using data from an accelerometer 5, [30] [31] [32] [33] [34] [35] [36] [37] [38] . 
Characteristics of included studies
Randomized controlled trials (RCTs)
An overview of the RCTs is listed in 
Prospective observational studies (POS)
An overview of the POS is listed in 
Cross-sectional studies (CSS)
A total of 41,816 participants were included across the 21 CSS. The characteristics of these CCS are listed in Physical Activity Survey" which measures SB in the last 7 days.
Sedentary Behaviour and biomarkers
Overview of biomarkers explored in the literature Table 2 provides an overview of the associations between SB and each biomarker system including:
anthropometric parameters, systemic parameters, blood lipids, glycaemic parameters, performance biomarkers, inflammatory biomarkers and others. A total of 63 biomarkers were evaluated (counting ratios of different biomarkers separately). , also performed in diabetes type 2 patients, revealed a positive association for SB with WC, too. The study from Lee et al.
33
, performed in the high risk osteoarthritis population showed lower gait speed and lower chair stand rate associated with higher levels of SB.
There were no statistically significant results for the study of Lynch et al. 34 investigating the association between SB with BMI, WC and insulin in a breast cancer survivor cohort. After the exclusion of these studies only 2 articles 6,61 with a low CASP-score ≤ 3 remained. The mean CASP score of RCTs was 5 out of 6, for cohort studies 5 out of 8 and for CSS 4.5 out of 6.
Risk of bias (quality) appraisal
Relation of SB and biomarkers
Sedentary behaviour and anthropometric and systemic biomarkers
Of the 15 studies exploring this biomarker, 9 demonstrated a positive association, including 1 RCT 44 and 1 POS 45 study ( CSS, but were not statistically significant in 4 RCTs. Relationships between SB and both systolic BP (3 of 11 studies reporting this biomarker found positive association) and diastolic BP (1 out of 10 studies found a positive associations) were found, whereas the majority showed non-significant results. Neck circumference and fat mass were positively correlated to SB but were investigated in only one RCT.
There was only limited or no evidence for the other anthropometric biomarkers (see Table 2 and 3). Table 2 and 3). Most RCTs didn't show statistically significant results, hence there is generally no evidence for an association of SB and blood lipids. Results linking SB and blood lipids mostly derived from CSS studies and thus should be interpreted accordingly.
Sedentary behaviour and blood lipids
Sedentary behaviour and glycaemic biomarkers
There was some indication found of an unfavourable impact of SB on fasting insulin levels, with statistically significant associations in 1 RCT 27 and 1 POS. Glucose levels did not appear to be related to SB in 3 RCTs 27, 41, 44 . Initially equivocal results in 2 CSS, with 1 positive 32 and 1 negative association 62 were clarified by contacting the author. In both studies SB was associated with higher blood glucose levels. The impact of SB on glycaemic biomarkers was limited and largely restricted to CSS ( Table 2 and 3), precluding definitive conclusion.
SB and muscle or physical performance biomarkers
Muscle tissue, performance, strength or other performance components were measured in 5 CSS (Bann et al.
31
, Santos et al.
36
, Sardinha et al.
37
, Lee et al.
33
, Larsen et al.
46
). 4 CSS also evaluated the association of SB and some performance biomarkers. Lee et al. 33 found a statistically significant negative correlation for SB with gait speed and chair stand rate. Santos et al. 36 constructed a composite Z-score of 6 performance biomarkers (6 minute walk test, 8 foot up and go, arm curl, chair stand rate, chair sit and reach or back scratch) which association with SB was significant negative, but he did not list the results separately. Bann et al. 31 and Sardinha et al. 37 did not find a significant correlation for SB and performance biomarkers.
SB and inflammatory biomarkers
There was a relative paucity of studies investigating inflammatory biomarkers and SB. CRP was investigated most frequently, although restricted to 4 CSS studies and 1 RCT, with only 2 CSS studies demonstrating that SB was positively associated with CRP. Only 2 CSS studies investigated IL-6 and SB, with 1 CSS finding a positive association. Given the limited number of studies and over reliance on CSS, the evidence base is inconclusive concerning the relationship between SB and inflammatory markers.
SB and other biomarkers
There was a distinct lack of studies investigating renal or bone biomarkers and SB. Only 1 study measured Vitamin D status 60 , but it was considered as too low in quality (see 9) in "Risk of bias appraisal"), because different points of time exposure and outcome were measured.
Leptin, which can be seen as adiposity-associated inflammation marker or regulation marker of hunger and fat metabolism, was higher with a higher amount of time spent sedentary (2 of 4 studies significant,
POS).
We could not identify any study investigating renal, cellular, respiratory, signal transduction or genetic biomarkers and SB meeting our inclusion criteria. None of the included studies evaluated the impact of SB on biomarkers of the gastrointestinal or peripheral/central nervous system, neither focused on steroid or hormone biomarkers.
Discussion
Within our comprehensive systematic review, findings from high quality papers showed mixed evidence for the association of SB and biomarkers. When statistically significant results were prominent, SB was associated in an unfavourable direction, especially in anthropometric (BMI, WC, neck circumference, fat mass), blood lipid (cholesterol, HDL, LDL), glycaemic (HbA1c, insulin, HOMA-IR, C-peptide) and hormonal (leptin) biomarkers. However several statistically non-significant study results were detected, many of which were of high quality. Some results of lower quality studies may be incidental findings or point to the existence of additional confounders, which are unaccounted so far.
Despite the relative paucity and equivocal nature of SB and biomarkers in older age, studies performed in younger cohorts strengthen the hypothesis that SB has harmful effects on biomarker levels. , showing a decrease in insulin-stimulated muscle activity phosphorylation and decreased peripheral insulin sensitivity by reducing daily activity for only 2 weeks, there appears to be a strong connection between SB and impaired glucose and insulin metabolism in younger age.
Our review identified some studies that evaluated the association between change in ST and systemic parameters, including blood pressure 5, 6, 63 , or heart rate 6
. Surprisingly and contrary to our expectation we identified no association between change of SB with blood pressure in 3 included RCTs 41, 42, 44 . The highlighted results of the four "risk population" studies showed associations for SB with biomarkers in the same direction as the studies performed in non-risk populations. The results from Lee et al.
33
, performed in the high risk osteoarthritis population with lower gait speed and lower chair stand rate associated with higher levels of SB can be argued over. This is the only study, which showed (remaining) statistically significant results for performance parameters. Even if SB measurements were adjusted for osteoarthritis pain index, osteoarthritis symptoms and other comorbidity indices, there could be still another unknown confounder, related to osteoarthritis triggering this biomarker outcome.
Surprisingly, there was an absence of studies (meeting our inclusion criteria) investigating SB and its possible impact on renal, muscle or bone biomarkers performed in the elderly. There is however good reason to believe that especially bone and muscle metabolism is influenced from SB due to multifactorial processes. Prioreschi et al. 84 results from a smaller cohort revealed low bone mass for higher levels of SB and a possible protective effect for bone mineral density with breaking up ST more frequently. Even in younger cohorts, ST has been implicated as being negatively related to changes in whole-body bone mineral density, lumbar spine bone mineral content, lumbar spine bone area and femoral neck 85 .
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